Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal

Rossella Elisei, M. Schlumberger, A. Driedger, C. Reiners, R. T. Kloos, S. I. Sherman, B. Haugen, C. Corone, E. Molinaro, L. Grasso, S. Leboulleux, I. Rachinsky, M. Luster, M. Lassmann, N. L. Busaidy, R. L. Wahl, F. Pacini, S. Y. Cho, J. Magner, A. PincheraP. W. Ladenson

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background: We previously demonstrated comparable thyroid remnant ablation rates in postoperative low-risk thyroid cancer patients prepared for administration of 3.7GBq 131I (100 mCi) after recombinant human (rh) TSH during T4 (L-T4) therapy vs. withholding L-T4 (euthyroid vs. hypothyroid groups). We now compared the outcomes of these patients 3.7 yr later. Patients and Methods: Fifty-one of the 63 original patients (28 euthyroid, 23 hypothyroid) participated. Forty-eight received rhTSH and serum thyroglobulin (Tg) sampling. A 131I whole-body scanwasperformed in43patients,andsuccessful ablationwasdefined by criteriafromthe previous study. Based on the criterion of uptake less than 0.1% in thyroid bed, 100% (43 of 43) remained ablated. When no visible uptake instead was used, five patients (four euthyroid, one hypothyroid) had minimal visible activity. When the TSH-stimulated Tg criterion was used, only two of 45 (one euthyroid, one hypothyroid) had a stimulated Tg level greater than 2 ng/ml. Results: No patient in either group died, and no patient declared disease free had sustained tumor recurrence. Nine (four euthyroid, five hypothyroid) had received additional 131I between the original and current studies due to detectable Tg or imaging evidence of disease; with follow-up, all now had a negative rhTSH-stimulated whole-body scan and seven (three euthyroid, four hypothyroid) had a stimulated serum Tg less than 2 ng/ml. Conclusions: In conclusion, after a median 3.7 yr, low-risk thyroid cancer patients prepared for postoperative remnant ablation either with rhTSH or after L-T4 withdrawal were confirmed to have had their thyroid remnants ablated and to have comparable rates of tumor recurrence and persistence.

Original languageEnglish (US)
Pages (from-to)4171-4179
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume94
Issue number11
DOIs
StatePublished - Nov 2009

Fingerprint

Thyrotropin Alfa
Thyroglobulin
Thyrotropin
Ablation
Thyroid Hormones
Thyroid Neoplasms
Thyroid Gland
Tumors
Whole Body Imaging
Recurrence
Sampling
Imaging techniques
Serum
Neoplasms

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. / Elisei, Rossella; Schlumberger, M.; Driedger, A.; Reiners, C.; Kloos, R. T.; Sherman, S. I.; Haugen, B.; Corone, C.; Molinaro, E.; Grasso, L.; Leboulleux, S.; Rachinsky, I.; Luster, M.; Lassmann, M.; Busaidy, N. L.; Wahl, R. L.; Pacini, F.; Cho, S. Y.; Magner, J.; Pinchera, A.; Ladenson, P. W.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 94, No. 11, 11.2009, p. 4171-4179.

Research output: Contribution to journalArticle

Elisei, R, Schlumberger, M, Driedger, A, Reiners, C, Kloos, RT, Sherman, SI, Haugen, B, Corone, C, Molinaro, E, Grasso, L, Leboulleux, S, Rachinsky, I, Luster, M, Lassmann, M, Busaidy, NL, Wahl, RL, Pacini, F, Cho, SY, Magner, J, Pinchera, A & Ladenson, PW 2009, 'Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal', Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 11, pp. 4171-4179. https://doi.org/10.1210/jc.2009-0869
Elisei, Rossella ; Schlumberger, M. ; Driedger, A. ; Reiners, C. ; Kloos, R. T. ; Sherman, S. I. ; Haugen, B. ; Corone, C. ; Molinaro, E. ; Grasso, L. ; Leboulleux, S. ; Rachinsky, I. ; Luster, M. ; Lassmann, M. ; Busaidy, N. L. ; Wahl, R. L. ; Pacini, F. ; Cho, S. Y. ; Magner, J. ; Pinchera, A. ; Ladenson, P. W. / Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. In: Journal of Clinical Endocrinology and Metabolism. 2009 ; Vol. 94, No. 11. pp. 4171-4179.
@article{937706e0cd8e47b0b5bdce2e85cc9a96,
title = "Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal",
abstract = "Background: We previously demonstrated comparable thyroid remnant ablation rates in postoperative low-risk thyroid cancer patients prepared for administration of 3.7GBq 131I (100 mCi) after recombinant human (rh) TSH during T4 (L-T4) therapy vs. withholding L-T4 (euthyroid vs. hypothyroid groups). We now compared the outcomes of these patients 3.7 yr later. Patients and Methods: Fifty-one of the 63 original patients (28 euthyroid, 23 hypothyroid) participated. Forty-eight received rhTSH and serum thyroglobulin (Tg) sampling. A 131I whole-body scanwasperformed in43patients,andsuccessful ablationwasdefined by criteriafromthe previous study. Based on the criterion of uptake less than 0.1{\%} in thyroid bed, 100{\%} (43 of 43) remained ablated. When no visible uptake instead was used, five patients (four euthyroid, one hypothyroid) had minimal visible activity. When the TSH-stimulated Tg criterion was used, only two of 45 (one euthyroid, one hypothyroid) had a stimulated Tg level greater than 2 ng/ml. Results: No patient in either group died, and no patient declared disease free had sustained tumor recurrence. Nine (four euthyroid, five hypothyroid) had received additional 131I between the original and current studies due to detectable Tg or imaging evidence of disease; with follow-up, all now had a negative rhTSH-stimulated whole-body scan and seven (three euthyroid, four hypothyroid) had a stimulated serum Tg less than 2 ng/ml. Conclusions: In conclusion, after a median 3.7 yr, low-risk thyroid cancer patients prepared for postoperative remnant ablation either with rhTSH or after L-T4 withdrawal were confirmed to have had their thyroid remnants ablated and to have comparable rates of tumor recurrence and persistence.",
author = "Rossella Elisei and M. Schlumberger and A. Driedger and C. Reiners and Kloos, {R. T.} and Sherman, {S. I.} and B. Haugen and C. Corone and E. Molinaro and L. Grasso and S. Leboulleux and I. Rachinsky and M. Luster and M. Lassmann and Busaidy, {N. L.} and Wahl, {R. L.} and F. Pacini and Cho, {S. Y.} and J. Magner and A. Pinchera and Ladenson, {P. W.}",
year = "2009",
month = "11",
doi = "10.1210/jc.2009-0869",
language = "English (US)",
volume = "94",
pages = "4171--4179",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal

AU - Elisei, Rossella

AU - Schlumberger, M.

AU - Driedger, A.

AU - Reiners, C.

AU - Kloos, R. T.

AU - Sherman, S. I.

AU - Haugen, B.

AU - Corone, C.

AU - Molinaro, E.

AU - Grasso, L.

AU - Leboulleux, S.

AU - Rachinsky, I.

AU - Luster, M.

AU - Lassmann, M.

AU - Busaidy, N. L.

AU - Wahl, R. L.

AU - Pacini, F.

AU - Cho, S. Y.

AU - Magner, J.

AU - Pinchera, A.

AU - Ladenson, P. W.

PY - 2009/11

Y1 - 2009/11

N2 - Background: We previously demonstrated comparable thyroid remnant ablation rates in postoperative low-risk thyroid cancer patients prepared for administration of 3.7GBq 131I (100 mCi) after recombinant human (rh) TSH during T4 (L-T4) therapy vs. withholding L-T4 (euthyroid vs. hypothyroid groups). We now compared the outcomes of these patients 3.7 yr later. Patients and Methods: Fifty-one of the 63 original patients (28 euthyroid, 23 hypothyroid) participated. Forty-eight received rhTSH and serum thyroglobulin (Tg) sampling. A 131I whole-body scanwasperformed in43patients,andsuccessful ablationwasdefined by criteriafromthe previous study. Based on the criterion of uptake less than 0.1% in thyroid bed, 100% (43 of 43) remained ablated. When no visible uptake instead was used, five patients (four euthyroid, one hypothyroid) had minimal visible activity. When the TSH-stimulated Tg criterion was used, only two of 45 (one euthyroid, one hypothyroid) had a stimulated Tg level greater than 2 ng/ml. Results: No patient in either group died, and no patient declared disease free had sustained tumor recurrence. Nine (four euthyroid, five hypothyroid) had received additional 131I between the original and current studies due to detectable Tg or imaging evidence of disease; with follow-up, all now had a negative rhTSH-stimulated whole-body scan and seven (three euthyroid, four hypothyroid) had a stimulated serum Tg less than 2 ng/ml. Conclusions: In conclusion, after a median 3.7 yr, low-risk thyroid cancer patients prepared for postoperative remnant ablation either with rhTSH or after L-T4 withdrawal were confirmed to have had their thyroid remnants ablated and to have comparable rates of tumor recurrence and persistence.

AB - Background: We previously demonstrated comparable thyroid remnant ablation rates in postoperative low-risk thyroid cancer patients prepared for administration of 3.7GBq 131I (100 mCi) after recombinant human (rh) TSH during T4 (L-T4) therapy vs. withholding L-T4 (euthyroid vs. hypothyroid groups). We now compared the outcomes of these patients 3.7 yr later. Patients and Methods: Fifty-one of the 63 original patients (28 euthyroid, 23 hypothyroid) participated. Forty-eight received rhTSH and serum thyroglobulin (Tg) sampling. A 131I whole-body scanwasperformed in43patients,andsuccessful ablationwasdefined by criteriafromthe previous study. Based on the criterion of uptake less than 0.1% in thyroid bed, 100% (43 of 43) remained ablated. When no visible uptake instead was used, five patients (four euthyroid, one hypothyroid) had minimal visible activity. When the TSH-stimulated Tg criterion was used, only two of 45 (one euthyroid, one hypothyroid) had a stimulated Tg level greater than 2 ng/ml. Results: No patient in either group died, and no patient declared disease free had sustained tumor recurrence. Nine (four euthyroid, five hypothyroid) had received additional 131I between the original and current studies due to detectable Tg or imaging evidence of disease; with follow-up, all now had a negative rhTSH-stimulated whole-body scan and seven (three euthyroid, four hypothyroid) had a stimulated serum Tg less than 2 ng/ml. Conclusions: In conclusion, after a median 3.7 yr, low-risk thyroid cancer patients prepared for postoperative remnant ablation either with rhTSH or after L-T4 withdrawal were confirmed to have had their thyroid remnants ablated and to have comparable rates of tumor recurrence and persistence.

UR - http://www.scopus.com/inward/record.url?scp=70349093388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349093388&partnerID=8YFLogxK

U2 - 10.1210/jc.2009-0869

DO - 10.1210/jc.2009-0869

M3 - Article

C2 - 19850694

AN - SCOPUS:70349093388

VL - 94

SP - 4171

EP - 4179

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -